MINNEAPOLIS,
July 31,
2024 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ: TECH) is pleased to announce the launch
of the Leo™ System. This next-generation Simple Western™ instrument
offers higher throughput, flexibility, and efficiency over the
current Jess™ and Abby™ Simple Western Systems. This
state-of-the-art instrument enables simultaneous processing of up
to 100 samples in a single 3-hour run, allowing scientists to
process more samples in a day. Leo also provides 4-times the
experimental size of Jess or Abby to facilitate quantitative assay
designs including standard curves, QC samples, blanks, duplicates
and reference standards. Leo's enhanced quantitative capabilities
empower customers to design rigorous bioanalytical methods for
use throughout the drug development process and in submissions to
regulatory agencies.
Simple Western instruments are fully automated,
capillary western systems designed to resolve proteins based on
molecular weight followed by immunodetection. Simple Western
Systems replace traditional western blotting workflows by offering
improvements in data quality and speed. The enhanced quantitation,
reproducibility and throughput Leo now provides makes it possible
for scientists to adopt western-based readouts in applications
where westerns are not typically used due to inadequate
reproducibility and lack of quantitation. Leo offers ELISA-like
protein quantitation with the specificity and size resolution
of western blotting, enabling new applications for western-based
assays ranging from target screening & validation, targeted
protein degradation, gene therapy potency assays, clinical
biomarker assays, and vaccine development.
"The upcoming introduction of the Leo System
reaffirms Bio-Techne's commitment to advancing protein analysis
technology. The ability to perform western analysis at this scale
is truly game changing and will allow the adoption of Leo as a
quantitative immunoassay platform in all stages of drug development
and commercialization," commented Will
Geist, President of Protein Sciences.
Leo is expected to begin shipping in calendar
year 2025.
Get a first look at the Leo System and explore
its capabilities at bio-techne.com/leo or click here to watch an
introductory video.
About Bio-Techne
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne products assist
scientific investigations into biological processes and the nature
and progress of specific diseases. They aid in drug discovery
efforts and provide the means for accurate clinical tests and
diagnoses. With thousands of products in its portfolio, Bio-Techne
generated approximately $1.1 billion
in net sales in fiscal 2023 and has approximately 3,100 employees
worldwide. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the Company
on social media at: Facebook, LinkedIn, Twitter or
YouTube.
Contact:
David Clair, Vice President,
Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-next-generation-high-throughput-simple-western-system-302210756.html
SOURCE Bio-Techne Corporation